<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324934</url>
  </required_header>
  <id_info>
    <org_study_id>AP-AS-24-ES</org_study_id>
    <nct_id>NCT01324934</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids</brief_title>
  <acronym>IBERICA</acronym>
  <official_title>Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurotrials Brasil Consultores Cientificos Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Recerca Clínica S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PsyConsult</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is the assessment of the overall graft rejection rate (acute,
      chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to
      standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a
      treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year
      after renal transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment became very slow.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the incidence of biopsy-proven acute allograft rejection after 12 months, including all types of rejections like: • acute rejection • chronic rejection • subclinical rejection</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of onset, histological severity and incidence of steroid resistance of acute and chronic rejections</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of initial DGF</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Graft survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints are the incidence of AEs/SAEs and ADRs</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-Fresenius S</intervention_name>
    <description>Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.
(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids).</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Signed and dated informed consent form,

          -  End-stage renal disease,

          -  Candidates for a first transplantation,

          -  Re-transplant patients are eligible if a graft loss after transplantation was NOT due
             to immunological reasons,

          -  Availability of a heart-beating cadaveric donor up to 70 years of age with a cold
             ischemia time shorter than 36 hours,

          -  Male or female patients between 18 to 75 years of age inclusive,

          -  Patients able to comply with all study related requirements,

          -  Patients able to receive oral medication,

          -  Women of childbearing age with a safe contraceptive method throughout the study.

        Exclusion Criteria

          -  Women who are pregnant or breast feeding,

          -  Known Human Immunodeficiency Virus,

          -  Hepatitis B Virus or Hepatitis C Virus infection,

          -  Severe actual viral, bacterial or fungal infection not adequately controlled,

          -  Patients with anamnestically known hypersensitivity to rabbit immunoglobulin
             antibodies or positive rabbit immunoglobulin skin test or known allergies to any
             component of the immunosuppressive drugs per protocol,

          -  Patients at high immunological risk defined as current PRA &gt; 25% or historical PRA &gt;
             50%,

          -  Patients receiving pre-transplant immunosuppressive treatment, including
             corticosteroids,

          -  Patients with current or history of malignancies (exception basal cell carcinoma or
             squamous cell carcinoma in remission),

          -  Patients with previous transplantation except 1st graft loss due to surgical
             complications,

          -  Patients receiving combined transplantation,

          -  Patients with major organ dysfunctions,

          -  Serious psychiatric or psychological disorders,

          -  Pre-transplant thrombocytopenia: &lt; 50,000 thrombocytes/µl, Pre-transplant leukopenia:
             &lt; 2,000 leukocytes/µl,

          -  Unable or unwilling to comply fully with the protocol,

          -  Participation in another study of an investigational medicinal product concurrently or
             within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Rengel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial Gregorio Maranon, Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental</name>
      <address>
        <city>Carnaxide</city>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Curry Cabral</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo António, SA</name>
      <address>
        <city>Porto</city>
        <zip>4090-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Juan Canalejo</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute rejection</keyword>
  <keyword>chronic rejection</keyword>
  <keyword>subclinical rejection</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>steroid-free</keyword>
  <keyword>kidney transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

